Corcept Therapeutics (CORT) 5.30 $CORT Corcept (CORT)

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 5:21 AM

Corcept Therapeutics (CORT) 5.30 $CORT

Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 34.47 (-0.28), BMY: 72.31 (+1.06), CORT: 5.30 (-0.11), CELG: 99.23 (+2.37)

Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
Marketwired - Thu Jun 02, 3:05PM CDT
MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 5.30 (-0.11)

Corcept beats 1Q profit forecasts
Automated Insights - Tue May 03, 3:35PM CDT
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $19,000 in its first quarter.
CORT: 5.30 (-0.11)

Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
Marketwired - Tue May 03, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 5.30 (-0.11)

Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
Marketwired - Fri Apr 29, 7:30AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 5.30 (-0.11)

Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers
Marketwired - Thu Apr 28, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today released data supporting the clinical advancement of its proprietary, selective cortisol modulator, CORT125134. The company has begun recruiting patients for a Phase 1/2 trial of the compound to treat patients with solid-tumor cancers. It also expects to begin recruiting patients for a Phase 2 study of CORT125134 to treat patients with Cushing's syndrome this quarter.
CORT: 5.30 (-0.11)

Corcept Therapeutics (CORT) Jumps: Stock Moves Up 9.6%
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 7:15AM CDT
Corcept Therapeutics Incorporated (CORT) shares rose almost 10% in the last trading session.
CALA: 4.16 (-0.08), CORT: 5.30 (-0.11)

Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 21.64 (unch), ARQL: 1.89 (+0.14), SCMP: 10.80 (+0.15), CORT: 5.30 (-0.11)

Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:25PM CDT
Aerie Pharmaceuticals, Inc. (AERI) announced the initiation of dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02%/0.005%.
SCMP: 10.80 (+0.15), AERI: 17.56 (-0.02), CORT: 5.30 (-0.11)

The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics
SYN: 1.85 (+0.07), GERN: 2.67 (-0.01), EPZM: 10.72 (-0.20), CORT: 5.30 (-0.11)

Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 7:15AM CDT
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 8% in the last trading session.
GLMD: 4.79 (-0.06), CORT: 5.30 (-0.11)

4 Surging Stocks Brokers Love in the Healthcare Sector
Arpita Dutt - Zacks Investment Research - Mon Mar 28, 8:16AM CDT
These four stocks are holding their own in a sector that has been in the news for the wrong reasons and have surged more than 10% in the last 4 weeks.
JNJ: 116.46 (+0.28), VRX: 21.64 (unch), SYN: 1.85 (+0.07), GERN: 2.67 (-0.01), AMGN: 149.81 (+0.39), EPZM: 10.72 (-0.20), CORT: 5.30 (-0.11)

Roche Files for FDA Approval of Elecsys BRAHMS Assay
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Roche Holdings, Inc. (RHHBY) announced that the company has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) with the FDA
ARQL: 1.89 (+0.14), SCMP: 10.80 (+0.15), CORT: 5.30 (-0.11)

Can The Uptrend Continue for Corcept Therapeutics (CORT)?
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 9:18AM CDT
Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance
CORT: 5.30 (-0.11)

Valeant to Get a New CEO Amid Turmoil, Ackman on Board
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 11:40AM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) current chief executive officer (CEO) J. Michael Pearson has recently decided to step down.
VRX: 21.64 (unch), ARQL: 1.89 (+0.14), SCMP: 10.80 (+0.15), CORT: 5.30 (-0.11)

Valeant Pharmaceuticals (VRX) Jumps: Stock Adds 7.4%
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 7:00AM CDT
Valeant (VRX) was a big mover last session, with its shares rising over 7% on the day.
VRX: 21.64 (unch), CORT: 5.30 (-0.11)

McKesson (MCK) to Restructure Operations, Lower Headcount
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:28PM CDT
McKesson Corporation (MCK) announced that management has undertaken a restructuring plan to lower its operating costs amid challenging business operations.
MCK: 181.53 (+2.26), ARQL: 1.89 (+0.14), SCMP: 10.80 (+0.15), CORT: 5.30 (-0.11)

3 Hedge Funds That Lost Hundreds of Millions on Valeant Stock
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 1:16PM CDT
Valeant Pharmaceuticals International Inc.'s (VRX) announcement of fourth quarter results and lowering of annual and quarterly guidance left its major institutional holders fuming and in the red.
VRX: 21.64 (unch), SCMP: 10.80 (+0.15), CORT: 5.30 (-0.11)

Forget Valeant, Buy These 5 Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Thu Mar 17, 9:10AM CDT
It's time to focus on drug stocks with interesting pipelines, good prospects and favorable Zacks Ranks.
SGYP: 3.80 (+0.04), VRX: 21.64 (unch), SCMP: 10.80 (+0.15), ARIA: 7.27 (+0.04), ENTA: 23.45 (+0.53), CORT: 5.30 (-0.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenera Care's Tech Triumph: Halving Falls with Simplicity

Every once in a while, a piece of tech comes along that makes you sit up and say, ‘Now that’s a game-changer!’ And with the recent rave reviews, Tenera Care seems to hit just that sweet spot for folks in the senior living game. By handing Dublin Glenn Memory Care the gold in the KISS category at the 2026 McKnight's Technology Awards, it’s clear the industry is...

Anixa Expands Global Footprint with Aussie Patent

Breaking New Ground in Cancer Immunotherapy Today feels like a pivotal day for Anixa Biosciences. Their announcement about securing a patent in Australia for their trailblazing breast cancer vaccine is like planting a flag on new, promising territory. This is no minor step; it's a strategic leap for the company as it strengthens its intellectual grip on the global...

NACD Honors Top Board Leaders with 2026 Awards

Celebrating Boardroom Mavericks at NACD Gala September 2026 has brought some sparkling recognition to the elites guiding today's corporate governance landscapes. The National Association of Corporate Directors (NACD) has announced their Directorship 100 honorees, tipping their hats to stellar individuals firing on all cylinders in the boardroom. Who's Getting the Nod?...

Lawsuit Targets Electrical Consultants' Labor Practices

Trouble Brews at Electrical Consultants, Inc. Right on the heels of a long workday, some employees of Electrical Consultants, Inc. seem to be getting a double whammy. The company is tangled up in a class action lawsuit lodged by the well-known Blumenthal Nordrehaug Bhowmik De Blouw LLP. This ain't your everyday grievance, folks; we're talking meal and rest period...

Nature-Based Solutions: The Economic And Community Impact

Harnessing Nature to Boost Economies You ever stop to think about how nature itself might just be the best investment? Well, the Walton Family Foundation surely does, betting big on nature-based solutions. Their latest initiative, 'Human Nature,' is shedding light on how these solutions aren't just saving ecosystems — they're fortifying economies and enriching...

Molex's VersaBeam Mini Pushes AI Data Center Limits

Game-Changer for AI Data Centers? Across the tech landscape, space is a premium, and Molex's new VersaBeam Mini arrives like a hail Mary in the fourth quarter. In AI data centers, squeezing down every single component counts—especially when optical density's in play. What we're seeing here is a potential paradigm shift. A 3x density improvement from a tiny 3.5 x 9 mm...

Navigating AI's New Era: Dresner's 2026 Findings

Big Insights in the AI World of 2026 Well folks, if there's one thing making waves in the boardrooms this year, it's AI. Dresner Advisory Services just threw down a gauntlet for companies with their fresh batch of reports focused on the dizzying world of AI. They ripped right into it, exploring how firms can bag a heap of benefits and deal with the hurdles that come with...

Lititz Mutual Embraces AI with Guidewire ProNavigator

It's not every day you see a company like Lititz Mutual making moves in the artificial intelligence (AI) arena. Based out of Lititz, Pennsylvania, this insurance firm has decided to shake things up with Guidewire's ProNavigator AI assistant. Forging New Paths in Insurance Lititz Mutual is set to inject some serious tech into their operations. The goal? Make life easier...

Spencer Peterman Hosts Eco-Friendly Wood Bowl Sale

Just when you think you've seen it all in the world of craftsmanship, along comes a dynamo like Spencer Peterman. For over 25 years, he's been turning what others discard into treasures. Fallen trees? Most folks see firewood. Spencer sees a future masterpiece. And now, he’s rolling out the welcome mat for his loyal customers with a special sale that runs until December...

U.N. Leaders Converge at NYSE, Forus Soars to $3B Valuation

A Busy Morning at the NYSE with Key Guests and Global Events In a world where high-stakes diplomacy and roaring market bells go hand in hand, today brings the U.S. Secretary of State, Marco Rubio, to the New York Stock Exchange. With the 81st Session of the United Nations General Assembly shaking up the Big Apple, the city finds itself at the intersection of politics and...